Clinical Trial Update: A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia [Phase 1]

View source ↗

Summary

Phase 1 study to determine the maximum tolerated dose of an investigational drug in adults with schizophrenia; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Investigator's investigational drug

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED | Results posted: 2020-05-08